[1]刘翔宇,王凌云.环杷明抑制肝星形细胞激活改善肝纤维化作用实验研究*[J].陕西医学杂志,2020,49(6):663-666.[doi:DOI:10.3969/j.issn.10007377.2020.06.006]
　LIU Xiangyu,WANG Lingyun..Effect of cyclopamine on inhibiting the activation of hepatic astrocyte and improving hepatic fibrosis[J].,2020,49(6):663-666.[doi:DOI:10.3969/j.issn.10007377.2020.06.006]
点击复制

环杷明抑制肝星形细胞激活改善肝纤维化作用实验研究*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年6期
页码:
663-666
栏目:
基础研究
出版日期:
2020-06-05

文章信息/Info

Title:
Effect of cyclopamine on inhibiting the activation of hepatic astrocyte and improving hepatic fibrosis
作者:
刘翔宇; 王凌云
山东省济宁市第一人民医院消化内科(济宁 272000)
Author(s):
LIU Xiangyu; WANG Lingyun.
Department of Gastroenterology,First People's Hospital of Jining,Shandong Province(Jining 272000)
关键词:
环杷明;  肝星状细胞;  肝纤维化;  动物模型;  HH信号通路;  小鼠
Keywords:
Cyclopamine;  Hepatic astrocytes;  Liver fibrosis;  Animal model;  HH Signaling pathway;  Mice
分类号:
R392.5
DOI:
DOI:10.3969/j.issn.10007377.2020.06.006
文献标志码:
A
摘要:
目的:探讨环杷明及维生素D3、白藜芦醇、姜黄素在改善肝纤维化中的作用效果并揭示相关机制。方法:构建CCl4诱导的肝纤维化小鼠模型,1个月后进行药物干预,分对照组和肝纤维化组,其中肝纤维化组又分为PBS治疗组、环杷明皮下注射组[5 mg/(kg·d)和10 mg/(kg·d)]、维生素D3皮下注射组[3 ng/(100g·d)]、白藜芦醇灌胃组[200 mg/(kg·d)]、姜黄素灌胃组[400 mg/(kg·d)],连续给药4周后处死小鼠。免疫组化检测小鼠肝损伤、纤维化、血管化。Western blot对肝纤维化[细胞外基质(ECM)积累情况]和星状胶质细胞激活相关蛋白进行检测。结果:环杷明、维生素D3、白藜芦醇、姜黄素等治疗后均可抑制ALT和AST表达(P<0.001),改善纤维化。环杷明组可显著抑制肝组织中CD31、α-SMA表达,且环杷明10 mg/kg浓度治疗效果好于5 mg/kg(P<0.001)。环杷明组可抑制肝组织中α-SMA、CollagenⅠ和TGF-β1表达,且环杷明10 mg/kg浓度治疗效果好于5 mg/kg。结论:环杷明、维生素D3、白藜芦醇和姜黄素均可降低转氨酶水平,抑制肝组织纤维化。环杷明可通过抑制抑制肝星状细胞激活、ECM和血管活化来改善肝纤维化,高剂量组效果更为显著。
Abstract:
Objective:To investigate the effect of cyclopa mine,vitamin D3,resveratrol and curcumin on the improvement of liver fibrosis,and to reveal the related mechanism.Methods:The mice model of liver fibrosis induced by CCl4 was established.One month later,drug intervention was performed,and the mice were divided into control group and liver fibrosis group.The liver fibrosis group was divided into PBS treatment group,cyclopa mine subcutaneous injection group [5 mg/(kg·d)and 10 mg/(kg·d)],vitamin D3 subcutaneous injection group [3 ng/(100g·d)],resveratrol intragastric injection group [200 mg/(kg·d)],curcumin intragastric injection group [400 mg/(kg·d)].The mice were killed after 4 weeks of continuous ad ministration.Immunohistochemistry was used to detect liver injury,fibrosis and vascularization in mice.Western blot was used to detect liver fibrosis [accumulation of extracellular matrix(ECM)]and activation of related proteins in astrocytes.Results:The expression of ALT and AST could be inhibited and the fibrosis could be improved after the treatment of cyclopa mine,vitamin D3,resveratrol and curcumin(P<0.001).The expression of CD31 and α-SMA in liver tissue was significantly inhibited in the cyclopamine subcutaneous injection group,and the therapeutic effect of 10 mg/kg of cyclopa mine was better than that of 5 mg/kg(P<0.001).The expression of α-SMA,collagen Ⅰ and TGF-β1 in liver tissue was inhibited in cyclopa mine subcutaneous injection group,and the therapeutic effect of cyclopa mine 10 mg/kg was better than that of 5 mg/kg.Conclusion:Cyclopa mine,vitamin D3,resveratrol and curcumin can reduce transa minase level and inhibit liver fibrosis.Cyclopa mine can improve hepatic fibrosis by inhibiting hepatic astrocytes activation,ECM and blood vessels activation,especially in the high dose group.

参考文献/References:

[1] Wang P,Koyama Y,Liu X,et al.Promising therapy candidates for liver fibrosis[J].Frontiers in Physiology,2016,7:47.
[2] Toosi AE.Liver fibrosis:causes and methods of assessment,a review[J].Romanian Journal of Internal Medicine,2015,53(4):304-314.
[3] Sun M,Kisseleva T.Reversibility of liver fibrosis[J].Clinics and Research in Hepatology and Gastroenterology,2015,39:60-63.
[4] Hernandez-Gea V,Friedman S L.Pathogenesis of liver fibrosis[J].Annual Review of Pathology:Mechanisms of Disease,2011,6:425-456.
[5] Zhang F,Hao M,Jin H,et al.Canonical hedgehog signalling regulates hepatic stellate cell-mediated angiogenesis in liver fibrosis[J].British Journal of Pharmacology,2017,174(5):409-423.
[6] Mejias M,Garcia-Pras E,Tiani C,et al.Beneficial effects of sorafenib on splanchnic,intrahepatic,and portocollateral circulations in portal hypertensive and cirrhotic rats[J].Hepatology,2009,49(4):1245-1256.
[7] Hennenberg M,Trebicka J,Stark C,et al.Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis[J].British Journal of Pharmacology,2009,157(2):258-270.
[8] Choi SS,Omenetti A,Syn WK,et al.The role of Hedgehog signaling in fibrogenic liver repair[J].The International Journal of Biochemistry & Cell Biology,2011,43(2):238-244.
[9] 吕艳艳,薛阳利,陶美花,等.黄芩苷联合干扰素α治疗乙型肝炎肝纤维化临床研究[J].陕西医学杂志,2018,47(5):643-645.
[10] Zhang Y,Li Y,Zhang L,et al.Mesenchymal stem cells:potential application for the treatment of hepatic cirrhosis[J].Stem Cell Research&Therapy,2018,9(1):59.
[11] 靳雯臻,谭晓川,文 瑾,等.靶向肝星状细胞治疗肝纤维化的纳米递送系统研究进展[J].中国医药导报,2019,16(9):34-37.
[12] Wang W,Chen K,Xia Y,et al.The hepatoprotection by oleanolic acid preconditioning:focusing on PPARα activation[J].PPAR Research,2018,2018:3180396.
[13] Wu F,Zhang Y,Sun B,et al.Hedgehog signaling:from basic biology to cancer therapy[J].Cell Chemical Biology,2017,24(3):252-280.
[14] 林春蕾,郭传勇.Hedgehog通路与肝纤维化关系的研究进展[J].胃肠病学和肝病学杂志,2012,21(10):909-911.
[15] Omenetti A,Choi S,Michelotti G,et al.Hedgehog signaling in the liver[J].Journal of Hepatology,2011,54(2):366-373.
[16] 禤传凤,罗伟生,陈国忠,等.中药活性成分干预肝纤维化分子信号通路的研究进展[J].中国药理学通报,2017,33(12):1638-1641.
[17] 靳祎祎,李琼瑜,赖子君,等.白花蛇舌草通过调控Hedgehog通路增加大肠癌耐药细胞的药物蓄积研究[J].康复学报,2016,26(3):34-39.

相似文献/References:

[1]徐志刚,曹 罡,程传涛,等.CTRP3通过TGF-β1/Smad 信号通路减弱肝星状细胞活性机制研究*[J].陕西医学杂志,2020,49(5):523.
　XU Zhigang,CAO Gang,CHENG Chuantao,et al.Mechanism of CTRP3 attenuating hepatic stellate cell activation through TGF-β1/Smad signal pathway[J].,2020,49(6):523.
[2]艾丁丁,罗伟生△,蒋云霞.动物肝纤维化模型建立研究进展*[J].陕西医学杂志,2020,49(7):907.[doi:DOI:10.3969/j.issn.10007377.2020.07.038]
　AI Dingding,LUO Weisheng,JIANG Yunxia..Progress in the establisment of animal liver fibrosis model[J].,2020,49(6):907.[doi:DOI:10.3969/j.issn.10007377.2020.07.038]
[3]刘 俊,曾 龙,高 云,等.长链非编码RNA YAF2-AS1通过调控微小RNA-141-3p表达抑制肝星状细胞活化实验研究[J].陕西医学杂志,2023,52(9):1120.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.002]
　LIU Jun,ZENG Long,GAO Yun,et al.Long-chain non-coding RNA YAF2-AS1 inhibits activation of hepatic stellate cells by regulating expression of microRNA-141-3p[J].,2023,52(6):1120.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.002]

备注/Memo

备注/Memo:
*山东省医药卫生科技发展项目(2017WS518)；山东省济宁市科技发展计划项目(2014JNJC13)
更新日期/Last Update: 2020-07-28